Investigators Assess Infection Risk with RA Biologics
Study Says 1 Biosimilar Switch Is OK; Jury Still Out on Multiple Switches
EU Grants Marketing Authorization for Hyrimoz; Plus FDA Rejects New Drug Application for Buprenorphine Sublingual Spray
Phase 3 Trial Results: Blisibimod for Lupus Shows Possible Efficacy
Guselkumab May Best Adalimumab for Psoriasis on the Scalp, Palms & Soles
FDA Update: Committee Recommends 2 mg Baricitinib Approval; HLH Identified as Serious Adverse Event for Lamotrigine
International Approvals for Guselkumab & Anakinra; Plus Adalimumab Biosimilar in Europe
Upadacitinib Proves Superiority to Adalimumab in Phase 3 RA Study
AbbVie, Samsung Bioepis in Deal; Humira Biosimilar U.S. Release in 2023
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 30
- Next Page »